Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas

International Journal of Radiation Oncology Biology Physics

Volumn 39, Issue 2 SUPPL., 1997, Pages 275-281

  Eschwège, François ^a   Sancho Garnier, Hélène ^a   Chassagne, Daniel ^a   Brisgand, Denis ^a   Guerra, Marta ^a   Malaise, Edmond Philippe ^a   Bey, Pierre ^b   Busutti, Luciano ^c   Cionini, Luca ^d   N'Guyen, Tan ^e   Romanini, Alberto ^f   Chavaudra, Jean ^a   Hill, Catherine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c USL Ventotto   (Italy)

^d Institute of Radiology   (Italy)

^e INSTITUT JEAN GODINOT   (France)

^f Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

Author keywords

Etanidazole; Head and neck carcinoma; Hypoxic cell sensitizer; Radiotherapy

Indexed keywords

ETANIDAZOLE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETANIDAZOLE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; TREATMENT FAILURE;

EID: 0030854147     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00327-1     Document Type: Article

References (14)

1. Berrino, F.; Sant, M.; Verdecchia, A.; Capocaccia, R.; Hakulinen, T.; Estève, J. Survival of cancer patients in Europe. Lyon: IARC 1995.
2. Brown, J. M.; Yu, N. Y.; Brown, D. M.; Lee, W. W. SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int. J. Radiat. Oncol. Biol. Phys. 7:699-703; 1981.
3. Chassagne, D.; Charreau, I.; Sancho-Garnier, H.; Eschwège, F.; Malaise, E. First analysis on tumor regression for the European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 22:581-584; 1992.
4. Coleman, C. N.; Halsey, R. S.; Cox, R. S.; Hirst, V.; Blaschke, T.; Howes, A.; Wasserman, T.; Urtasun, R. C.; Pajak, T.; Hancock, S.; Philip, T. L.; Noll, L. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Res. 47:319-322; 1987.
5. Gatenby, R. A.; Kessler, H. B.; Rosenblum, J. S.; Coiä L. R.; Moldofsky, P. J.; Hartz, W. H.; Broder, G. J. Oxygen distribution in squamous cell carcinoma metastasis and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14:831-838; 1988.
6. Hockel, M.; Vorndran, B.; Shlenger, K.; Baubmann, E.; Knapstein, G. Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol. Oncol. 51:141-149; 1993.
7. Huilgol, N. G.; Chatterjee, N.; Mehta, A. R. An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 34:1121-1124; 1996.
8. Kéraudy, K.; Maury, A.; Eschwège, F.; Chassagne, D.; Beauvais, H.; Chavaudra, J. Evaluation des données dosimétriques individuelles des patients d'un essai thérapeutique international en radiothérapie. Bull Cancer/Radiother. 81:206-220; 1994.
9. Lartigau, E.; Leridant, A. M.; Lambin, P.; Weeger, P.; Martin, L.; Sigal, R.; Lusinchi, A.; Luboinski, B.; Eschwége, F.; Guichard, M. Oxygenation of head and neck tumors. Cancer 71:2319-2325; 1993.
10. Lee, D. L.; Cosmatos, D.; Marcial, V. A. et al. Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus Etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32:567-576; 1995.
11. Overgaard, J.; Hansen, H. S.; Andersen, A. P.; Hjelm-Hansen, M.; Jorgensen, K.; Sandberg, E.; Berthelsen, A.; Hammer, R.; Pedersen, M. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int. J. Radiat. Oncol. Biol. Phys. 16:1065-1068; 1989.
12. Overgaard, J.; Hansen, H. S.; Lindelov, B.; Overgaard, M.; Jorgensen, K.; Rusmusson, B. Nimorazole as a hypoxic radiosensitizer in the treatment of suppraglottic larynx and pharyngeal carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. Suppl. 20:143-149; 1991.
13. Schemper, M.; Smith, T. L. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 17:343-346; 1996.
14. Taves, D. R. Minimization: A new method of assigning patients to treatment and control groups. Clin. Pharmacol. Ther. 15:443-453; 1994.